Perylene-1,2-dione | 106220-24-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: Perylene-1,2-dione
• CAS: 106220-24-0
• 化学式: C₂₀H₁₀O₂
• 分子量: 282.3
• InChiKey: IYYMDGDZPDXTGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• SHIGA TOXIN B-SUBUNIT/CHEMOTHERAPEUTICS CONJUGATES
  申请人：Johannes Ludger

  公开号：US20110152252A1

  公开（公告）日：2011-06-23

  The present invention relates to the use of a Shiga toxin B-subunit moiety as carrier for therapeutic agents, for example, anti-cancer agents such as anti-cancer agents that require intracellular uptake to exert their anti-cancer effects. In particular, the present invention provides conjugates comprising a Shiga toxin moiety covalently linked to an anti-cancer agent through a self-immolative spacer, and methods of using such conjugates to increase cellular uptake and/or specificity for cancer cells of the anti-cancer drug. Also provided are methods of treatment involving administration of such conjugates, and pharmaceutical compositions and kits useful for carrying out such methods of treatment.

  本发明涉及使用志贺毒素B亚基部分作为治疗剂如抗癌剂的载体，例如，需要胞内摄取以发挥其抗癌效果的抗癌剂。尤其地，本发明提供了一种偶联物，该偶联物包括通过自焚间隔物与抗癌剂共价连接的志贺毒素部分，以及使用这种偶联物来增加抗癌药物的细胞摄取和/或对癌细胞的特异性的方法。还提供了涉及施用这种偶联物的治疗方法，以及用于执行这种治疗方法的药物组合物和试剂盒。
• [EN] MACROMOLECULAR PRODRUGS FOR HARD TISSUE AND METHODS OF USE THEREOF<br/>[FR] PROMÉDICAMENTS MACROMOLÉCULAIRES POUR TISSU DUR ET LEURS PROCÉDÉS D'UTILISATION
  申请人：NEW YORK SOC RUPTURED & CRIPPLED MAINTAINING HOSPITAL FOR SPECIAL SURGERY

  公开号：WO2014036548A1

  公开（公告）日：2014-03-06

  Compositions for intravenous administration and methods for treating bone diseases, disorders, and fractures comprising macromolecular prodrugs of hydrophobic bone anabolic agents are provided. Specifically, novel macromolecular amphiphilic prodrugs wherein at least three molecules of simvastatin are conjugated to polyethylene glycol, which spontaneously form micelles in aqueous solutions are provided.

  提供用于静脉给药的组成物以及包括疏水性骨骼合成剂的巨分子前药治疗骨骼疾病、紊乱和骨折的方法。具体而言，提供新颖的巨分子两亲性前药，其中至少三分子辛伐他汀与聚乙二醇共轭，它们在水溶液中自发形成胶束。
• [EN] SUBSTITUTED 1H-INDAZOL-1-OL ANALOGS AS INHIBITORS OF BETA CATENIN/TCF PROTEIN-PROTEIN INTERACTIONS<br/>[FR] ANALOGUES SUBSTITUÉS DE 1H-INDAZOL-1-OL EN TANT QU'INHIBITEURS D'INTERACTIONS PROTÉINE-PROTÉINE BÊTA-CATÉNINE/TCF
  申请人：UNIV UTAH RES FOUND

  公开号：WO2013120045A1

  公开（公告）日：2013-08-15

  In one aspect, the invention relates to substituted lH-benzo[d][l,2,3]triazol-l-ol analgoues, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g. various tumors and cancers, associated with β-catenin/Tcf protein- protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在一个方面，该发明涉及替代的1H-苯并[d][1,2,3]三唑-1-醇类似物，其衍生物以及相关化合物；制备这些化合物的合成方法；包括这些化合物的药物组合物；以及利用这些化合物和组合物治疗与β-连环蛋白/Tcf蛋白相互作用功能障碍相关的疾病，例如各种肿瘤和癌症的方法。本摘要旨在作为在特定领域进行搜索的扫描工具，并不打算限制本发明。
• Cytotoxic nucleoside analog compound 003 for treating cancer
  申请人：Uckun M. Fatih

  公开号：US20060046972A1

  公开（公告）日：2006-03-02

  The present invention provides pharmaceutical compositions comprising Compound 003 or metabolites thereof in combination with one or more carboxylesterase inhibitors. The invention provides methods for inhibiting cellular proliferation associated with proliferative cell disorders in a subject by administering Compound 003 or metabolites thereof. The invention also provides methods for arresting the cell cycle. Methods of inhibiting proliferation of cells for treatment of cancer by administering Compound 003 are described.

  本发明提供了一种制剂，包括化合物003或其代谢物与一种或多种羧酯酶抑制剂的组合。本发明提供了一种通过给予化合物003或其代谢物来抑制与增殖性细胞疾病相关的细胞增殖的方法。本发明还提供了一种阻止细胞周期的方法。本发明还描述了通过给予化合物003来抑制癌细胞增殖的治疗癌症的方法。
• Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
  申请人：Chatterjee-Kishore Moitreyee

  公开号：US20060252045A1

  公开（公告）日：2006-11-09

  The invention discloses compositions, compounds, apparatuses and methods of using them to study bone mineralization and identify agents that regulate bone mineralization. Methods of using bone mineralization gene profiles and signatures for compound screening and research are also disclosed. Reagents for modulating bone mineralization are provided for both therapeutic and research usage.

  本发明揭示了用于研究骨矿化和鉴定调节骨矿化的药物的组合物、化合物、装置和使用方法。还揭示了使用骨矿化基因谱和签名进行化合物筛选和研究的方法。提供了用于调节骨矿化的试剂，可用于治疗和研究。